Uncategorized
AKB-9778, anti-VEGF combination therapy yields favorable results in TIME-2 trial
WAIKOLOA, Hawaii — AKB-9778 in combination with an anti-VEGF agent for the treatment of patients with diabetic macular edema yielded favorable results in the phase 2 TIME-2 study, according to a speaker here. “TIME-2 results support future development of AKB-9778 in combination with anti-VEGF therapy for the treatment of DME,” Peter K. Kaiser, MD, said at Retina 2016.